Author

Jacqueline A Nicholas

Institutions: OhioHealth, Riverside Methodist Hospital

Observed institutions: OhioHealth, Riverside Methodist Hospital

OpenAlex ID: A5135095602

Efficacy and safety of a bodyweight–adjusted higher dose of ocrelizumab in relapsing (MUSETTE) and primary progressive (GAVOTTE) multiple sclerosis: two multicentre, randomised, double-blind, parallel-group phase 3b trials

2026 · Stephen L Hauser, Gavin Giovannoni, et al. · The Lancet · 3

Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS)

2026 · Emma C Tallantyre, Sarah M Planchon, et al. · Multiple Sclerosis Journal

Works count: 2

Citation count: 3

H-index: 1

I10-index: